<?xml version="1.0" encoding="UTF-8"?>
<p id="para0011">Early clinical experience of remdesivir therapy in a female nurse from Scotland with Ebola meningoencephalitis, which was supported by the detection of Ebola virus RNA in plasma and cerebrospinal fluid, its first use for Ebola virus infection in humans, was reported in 2016 
 <xref rid="bib0022" ref-type="bibr">[22]</xref>. She was successfully treated with high-dose corticosteroids and 14 days of remdesivir therapy (once-daily infusion of 150 mg over 2 h for 2 days, and then daily 225 mg for another 12 days). No serious clinical or biochemical events occurred except a transient rise of serum amylase level.
</p>
